KR102885515B1 - 암의 치료 - Google Patents

암의 치료

Info

Publication number
KR102885515B1
KR102885515B1 KR1020207035232A KR20207035232A KR102885515B1 KR 102885515 B1 KR102885515 B1 KR 102885515B1 KR 1020207035232 A KR1020207035232 A KR 1020207035232A KR 20207035232 A KR20207035232 A KR 20207035232A KR 102885515 B1 KR102885515 B1 KR 102885515B1
Authority
KR
South Korea
Prior art keywords
ser
val
thr
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207035232A
Other languages
English (en)
Korean (ko)
Other versions
KR20210010486A (ko
Inventor
샤드 에사 압둘라
아쇼크 쿠마르 굽타
쉬양 송
Original Assignee
메디뮨 리미티드
이나뜨 파르마 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 리미티드, 이나뜨 파르마 에스.에이. filed Critical 메디뮨 리미티드
Publication of KR20210010486A publication Critical patent/KR20210010486A/ko
Application granted granted Critical
Publication of KR102885515B1 publication Critical patent/KR102885515B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207035232A 2018-05-15 2019-05-14 암의 치료 Active KR102885515B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671521P 2018-05-15 2018-05-15
US62/671,521 2018-05-15
PCT/EP2019/062305 WO2019219658A1 (en) 2018-05-15 2019-05-14 Treatment of cancer

Publications (2)

Publication Number Publication Date
KR20210010486A KR20210010486A (ko) 2021-01-27
KR102885515B1 true KR102885515B1 (ko) 2025-11-12

Family

ID=66752041

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207035232A Active KR102885515B1 (ko) 2018-05-15 2019-05-14 암의 치료

Country Status (13)

Country Link
US (1) US12209126B2 (cg-RX-API-DMAC7.html)
EP (1) EP3793607A1 (cg-RX-API-DMAC7.html)
JP (2) JP7531404B2 (cg-RX-API-DMAC7.html)
KR (1) KR102885515B1 (cg-RX-API-DMAC7.html)
CN (1) CN112203691A (cg-RX-API-DMAC7.html)
AU (2) AU2019270277B9 (cg-RX-API-DMAC7.html)
CA (1) CA3099820A1 (cg-RX-API-DMAC7.html)
EA (1) EA202092696A1 (cg-RX-API-DMAC7.html)
IL (1) IL278618B2 (cg-RX-API-DMAC7.html)
MA (1) MA52627A (cg-RX-API-DMAC7.html)
SG (1) SG11202011117VA (cg-RX-API-DMAC7.html)
TW (1) TW202011989A (cg-RX-API-DMAC7.html)
WO (1) WO2019219658A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015316993B2 (en) 2014-09-16 2021-03-18 Innate Pharma Treatment regimens using anti-NKG2A antibodies
TWI924623B (zh) 2018-03-13 2026-05-11 法商天賜製藥公司 頭頸癌之治療
WO2021219048A1 (zh) * 2020-04-30 2021-11-04 迈威(上海)生物科技股份有限公司 一种靶向nkg2a和pd-l1的双特异性抗体及应用
CN116096754A (zh) * 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法
EP4150058A4 (en) * 2020-05-13 2024-06-19 Nanjing Legend Biotech Co., Ltd. COMPOSITIONS AND METHODS FOR REDUCING HOST REJECTION OF ALLOGENIC CELLS USING MONKEY ICP47 AND VARIANTS THEREOF
CN117730094A (zh) * 2021-07-16 2024-03-19 克莱格医学有限公司 用于肿瘤免疫学的组合物和方法
IL311736A (en) * 2021-10-04 2024-05-01 Servier Lab Cancer therapy targeting nkg2a
CA3241115A1 (en) * 2021-12-14 2023-06-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to cd94/nkg2a heterodimer polypeptides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106656A1 (en) * 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017125532A1 (en) * 2016-01-21 2017-07-27 Innate Pharma Neutralization of inhibitory pathways in lymphocytes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
CA2487932A1 (en) 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
RU2481356C2 (ru) 2004-12-28 2013-05-10 Иннейт Фарма Моноклональные антитела против nkg2a
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
DK2038306T3 (en) 2006-06-30 2015-03-09 Novo Nordisk As ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
MX342131B (es) 2011-06-17 2016-09-14 Novo Nordisk As Eliminacion selectiva de celulas erosivas.
RU2017105425A (ru) * 2014-08-28 2018-09-28 Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины
KR20250007689A (ko) * 2014-09-16 2025-01-14 이나뜨 파르마 에스.에이. 림프구에서의 억제 경로의 중화
AU2015316993B2 (en) 2014-09-16 2021-03-18 Innate Pharma Treatment regimens using anti-NKG2A antibodies
EP3209687A1 (en) 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
TWI924623B (zh) 2018-03-13 2026-05-11 法商天賜製藥公司 頭頸癌之治療

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106656A1 (en) * 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017125532A1 (en) * 2016-01-21 2017-07-27 Innate Pharma Neutralization of inhibitory pathways in lymphocytes

Also Published As

Publication number Publication date
JP2024102055A (ja) 2024-07-30
JP2021523170A (ja) 2021-09-02
CN112203691A (zh) 2021-01-08
WO2019219658A1 (en) 2019-11-21
CA3099820A1 (en) 2019-11-21
IL278618B1 (en) 2025-07-01
AU2025200275B2 (en) 2026-06-11
SG11202011117VA (en) 2020-12-30
AU2019270277A1 (en) 2021-01-07
KR20210010486A (ko) 2021-01-27
US20210253694A1 (en) 2021-08-19
US12209126B2 (en) 2025-01-28
AU2025200275A1 (en) 2025-01-30
EA202092696A1 (ru) 2021-04-05
MA52627A (fr) 2021-03-24
TW202011989A (zh) 2020-04-01
IL278618B2 (en) 2025-11-01
EP3793607A1 (en) 2021-03-24
JP7531404B2 (ja) 2024-08-09
AU2019270277B9 (en) 2024-12-05
AU2019270277B2 (en) 2024-11-21
IL278618A (cg-RX-API-DMAC7.html) 2021-01-31

Similar Documents

Publication Publication Date Title
KR102543739B1 (ko) 림프구에서의 억제 경로의 중화
US12209126B2 (en) Treatment of cancer
JP2023055871A (ja) 抗nkg2a抗体を使用した治療計画
RU2769569C2 (ru) Нейтрализация ингибиторных путей в лимфоцитах
CN112004828B (zh) 头颈癌的治疗
JP2022500410A (ja) 非マイクロサテライト高不安定性/ミスマッチ修復の良好な結腸直腸がんを処置するためのpd−1アンタゴニストおよびlag3アンタゴニストの組み合わせ
EA049949B1 (ru) Лечение рака
KR20250112761A (ko) 항-cd39 항체를 포함하는 암의 신보조 치료를 위한 조성물 및 방법
HK40110316A (en) Neutralization of inhibitory pathways in lymphocytes
NZ729207B2 (en) Neutralization of inhibitory pathways in lymphocytes

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)